DAZATRO
Live / Applied — First extension granted (statement of use) (as of 17 Dec 2025)
What this means for you
Not registered yet, but its 10 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99034925
- Mark type
- Stylized text
- Filed
- 10 Feb 2025
- Published for opposition
- 06 May 2025
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 18 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Dec 2025 — SOU EXTENSION 1 GRANTED
- 17 Dec 2025 — SOU EXTENSION 1 FILED
- 17 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 May 2025 — PUBLISHED FOR OPPOSITION
- 30 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 04 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 Mar 2025 — ASSIGNED TO EXAMINER
- 10 Feb 2025 — APPLICATION FILING RECEIPT MAILED
- 10 Feb 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Feb 2025 — NEW APPLICATION ENTERED